We further analyzed published single-cell RNA-seq data (Published dataset B, Supplementary Table 7) [12] and found that BTKi treatment downregulated the expression of APOBEC3C in CLL B cells from two patients and APOBEC3G in CLL B cells of all four patients (Fig. 1E and Supplementary Fig. 1D, E), which indicates that the BTKi induced downregulation of APOBEC3s is generally consistent among most of the CLL B cells. The gene discussed is APOBEC3C; the disease is B-cell chronic lymphocytic leukemia.